An Antibody-Drug Conjugate (ADC) comprises a drug linked to an anitbody. The anitbody binds selectively to cancer cells to deliver the drug into the cell.

The antibody-drug conjugate (ADC) field is advancing at an unprecedented pace, with groundbreaking innovations and soaring investment. A 33% rise in new drugs, a surge in clinical trials, and ...

Puxitatug samrotecan (P-Sam), an investigational antibody-drug conjugate (ADC) targeting B7-H4-expressing tumors, showed promising efficacy in patients with advanced or metastatic endometrial cancer, ...

Antibody–drug conjugates (ADCs) represent a breakthrough in cancer therapy, combining the precision of monoclonal antibodies with powerful chemotherapeutic drugs. While ADC development is accelerating ...

"Today marks a transformative moment as we reintroduce ourselves as Whitehawk Therapeutics – a focused oncology company combining science ... portfolio of promising ADC assets," said David ...